Découvrez le nouveau Chem-Impex : là où l'innovation commence par une liaison.

Catalog Number:
37724
CAS Number:
73963-72-1
Cilostazol
Purity:
≥ 99 % (dosage)
Synonym(s):
6-[4-(1-cyclohexyl-1 H -tétrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
Documents
$18.50 /1G
Taille
Request Bulk Quote
Informations sur le produit

Cilostazol is a potent phosphodiesterase III inhibitor, primarily utilized in the management of intermittent claudication, a condition characterized by muscle pain due to inadequate blood flow. This compound enhances blood flow by inhibiting platelet aggregation and promoting vasodilation, making it a valuable therapeutic agent in cardiovascular health. Cilostazol's unique mechanism of action not only alleviates symptoms associated with claudication but also improves walking distance and overall quality of life for patients.

In addition to its primary use in treating peripheral vascular disease, Cilostazol is being explored for its potential benefits in other areas, such as stroke prevention and improving outcomes in patients with coronary artery disease. Its favorable safety profile and effectiveness make it a preferred choice among healthcare professionals. Researchers and industry professionals can leverage Cilostazol's properties for innovative applications in drug development and clinical research, contributing to advancements in cardiovascular therapies.

Numéro CAS 
73963-72-1
Formule moléculaire
C20H27N5O2
Poids moléculaire 
369.47
Point de fusion 
158 - 162 °C
Informations générales
Numéro CAS 
73963-72-1
Formule moléculaire
C20H27N5O2
Poids moléculaire 
369.47
Point de fusion 
158 - 162 °C
Propriétés
Informations complémentaires sur la propriété à venir prochainement !
-
Sécurité et réglementation
Matières dangereuses
-
Antibiotique
-
Réglementé par la DEA
Non
Avertissements 
-
Applications

Cilostazol is widely utilized in research focused on:

  • Cardiovascular Health: Primarily used to treat intermittent claudication, cilostazol improves blood flow and reduces pain during physical activity, making it essential for patients with peripheral artery disease.
  • Anti-platelet Activity: Its ability to inhibit platelet aggregation makes cilostazol valuable in preventing thrombotic events, particularly in patients at risk for stroke or heart attack.
  • Research on Metabolic Disorders: Studies indicate cilostazol may have beneficial effects on insulin sensitivity and lipid profiles, making it a candidate for research in diabetes and metabolic syndrome.
  • Neuroprotective Effects: Emerging research suggests cilostazol may offer neuroprotective benefits, potentially aiding in the treatment of neurodegenerative diseases such as Alzheimer’s.
  • Combination Therapies: Cilostazol is often explored in combination with other medications to enhance therapeutic outcomes, particularly in cardiovascular and metabolic health, providing a synergistic effect that can improve patient care.

Citations